Rutin trihydrate

CHF 122.00
In stock
CDX-R0066-G100100 gCHF 122.00
CDX-R0066-G500500 gCHF 489.00
More Information
Product Details
Synonyms Rutoside; Phytomelin; Sophorin; Birutan; Eldrin; Birutan Forte; Rutin trihydrate; Globularicitrin; Violaquercitrin; Quercetin rutinoside
Product Type Chemical
Formula C27H30O16 . 3H2O
MW 664.5
CAS 250249-75-3
Purity Chemicals ≥95% (HPLC)
Appearance Light yellow powder.
Solubility Soluble in DMSO or pyridine.
Declaration Manufactured by Chemodex.
Other Product Data

Click here for Original Manufacturer Product Datasheet
Our product description may differ slightly from the original manufacturers product datasheet.

Smiles O=C1C2=C(O)C=C(O)C=C2OC(C3=CC(O)=C(O)C=C3)=C1O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]5[C@H](O)[C@H](O)[C@@H](O)C(C)O5)O4
Shipping and Handling
Shipping AMBIENT
Short Term Storage +20°C
Long Term Storage +20°C
Handling Advice Protect from light and moisture.
Use/Stability Stable for at least 2 years after receipt when stored at +20°C.
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF

A polyphenolic flavonoid that acts as an antioxidant and NO scavenger. It can attenuate peroxide production in glial cells by acting as a free radical scavenger and protect renal cells from oxidative injury. Inclusion of rutin in the diet of rats significantly reduced the appearance of single-strand breaks in nuclear DNA caused by hepatocarcinogens aflatoxin B1 and N-nitrosodiumethylamine. This protection from DNA damage was found to be due to a reduction in the induction of repair enzymes polymerase, DNA polymerase β and DNA ligase. Since DNA damage and inefficient repair are thought to initiate the process of carcinogenesis, effects of rutin on these functions suggests a protective role of this flavonoid against carcinogenesis induced by chemical carcinogens. Rutin ameliorates obesity through brown fat activation.

Product References

(1) I.B. Afanas'ev, et al.; Biochem. Pharmacol. 38, 1763 (1989) | (2) R.P. Webster, et al.; Cancer Lett. 109, 185 (1996) | (3) E.A. Ostrakhovitch & I.B. Afanas'ev; Biochem. Pharmacol. 62, 743 (2001) | (4) N. Kamalakkannan & P.S. Prince; Basic Clin. Pharmacol. Toxicol. 98, 97 (2006) | (5) J.P. Lin, et al.; Leuk. Res. 33, 823 (2009) | (6) R. Lapa Fda, et al.; J. Pharm. Pharmacol. 63, 875 (2011) | (7) S.W. Wang, et al.; Neurotoxicology 33, 482 (2012) | (8) X. Yuan, et al.; FASEB J. 31, 333 (2016)

© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.